Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Prelude makes a further investment in Sciona


28 February 2005 -- Prelude Trust plc (“Prelude”), the investment trust that specialises in early stage, technology-based businesses has invested a further US$750,000 in Sciona Inc. This investment is part of a further US$4.25 million raised as a second closing of the September 2004 financing round. Prelude and its co-investors Burrill & Co. and BASF Venture Capital GmbH have been joined by new investor Bioventures Inc. Prelude now owns 23.5% of the issued share capital of Sciona.

Sciona develops DNA screens for common gene variants that affect an individual’s response to food, medications and the environment. These genetic screens serve as the basis for providing personalized, science-based health and lifestyle advice to consumers and can help companies customize personal care and nutrition products. Sciona’s field of genetic personalization is a rapidly growing discipline aimed at optimal health by creating products and services tailored to an individual’s genetic makeup. Sciona’s CellfTM genetic screen gives consumers nutritional guidelines – based on individual genetic profiles – to empower individuals to make better health decisions specific to their individual genetic makeup.

In addition to its genetic personalization work, Sciona provides research capabilities for large food, nutritional supplement and functional food companies interested in analyzing particular product ingredients as they relate to the normal genetic variations found in healthy individuals.

Rob James, a Director of Sciona Inc. and Prelude Ventures, commented: “Since our last investment Sciona has changed dramatically. The company has relocated to Boulder, Colorado where there is a flourishing biotechnology industry and has also successfully recruited Jim Bruce to be the Company’s new CEO. Jim was formerly CEO of Madaus Inc. a global pharmaceutical and nutraceutical company and brings with him substantial experience of the health and pharmaceutical industries. The potential of enhancing an individual’s ‘wellness’ by linking information on diet and lifestyle with DNA and harmonising the two is a topic attracting a lot of interest. With its leading position, Sciona is well placed to take advantage of the emergence of this new and exciting market.

“This is another important milestone for our company and further validates our position as a leader in this new and growing area of nutrition genetics,” said Jim Bruce, president and CEO of Sciona. “We are pleased to have such a strong set of investors. With their backing, we will finalize the move of our headquarters from the U.K. to Boulder, fund R&D for outcome validation studies, and proceed with market testing and rollout.”

For further information, please visit www.prelude-ventures.com
xx


Publisher Contact Information:

Prelude Ventures Limited
+44 (0)1954 288 090
rob.james@prelude-ventures.com

Company profile of DFJ Esprit (formerly Prelude Ventures Ltd.)
Past press releases of DFJ Esprit (formerly Prelude Ventures Ltd.).

Data


26,229
Tech investments
From our Online Data Service
16,944
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.